...
search icon
kalv-img

Kalvista Pharmaceuticals Inc Share Price

KALV
NMQ
$15.45
+$0.46
(3.07%)
1D
Industry: Biotechnology Sector: Health Care

Kalvista Pharmaceuticals Inc Analyst Forecast

Kalvista Pharmaceuticals Inc Share Price Chart

Kalvista Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$757.69M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
475.02K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.35
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$9.23 L
$19 H
$15.45

About Kalvista Pharmaceuticals Inc, Common Stock

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Kalvista Pharmaceuticals Inc Stock Returns

Time FrameKALVSectorS&P500
1-Week Return-0.39%0.72%-1.31%
1-Month Return0.91%1.27%0.78%
3-Month Return8.27%3.13%3.46%
6-Month Return15.82%15.81%6.19%
1-Year Return57.98%8.89%11.68%
3-Year Return97.82%20.79%71.21%
5-Year Return-60.11%35.89%74.81%
10-Year Return76.66%138.44%256.59%

Kalvista Pharmaceuticals Inc Financials

Apr '21Apr '22Apr '23Apr '24Apr '255YR TREND
Total Revenue12.69M----[{"date":"2021-04-30","value":100,"profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true},{"date":"2025-04-30","value":"-","profit":true}]
Cost of Revenue41.29M743.00K802.00K86.17M941.00K[{"date":"2021-04-30","value":47.91,"profit":true},{"date":"2022-04-30","value":0.86,"profit":true},{"date":"2023-04-30","value":0.93,"profit":true},{"date":"2024-04-30","value":100,"profit":true},{"date":"2025-04-30","value":1.09,"profit":true}]
Gross Profit(41.29M)(743.00K)(802.00K)(86.17M)(941.00K)[{"date":"2021-04-30","value":-4128600000,"profit":false},{"date":"2022-04-30","value":-74300000,"profit":false},{"date":"2023-04-30","value":-80200000,"profit":false},{"date":"2024-04-30","value":-8616700000,"profit":false},{"date":"2025-04-30","value":-94100000,"profit":false}]
Gross Margin(325.34%)----[{"date":"2021-04-30","value":-325.34,"profit":false},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true},{"date":"2025-04-30","value":"-","profit":true}]
Operating Expenses16.64M96.61M110.87M54.28M188.00M[{"date":"2021-04-30","value":8.85,"profit":true},{"date":"2022-04-30","value":51.39,"profit":true},{"date":"2023-04-30","value":58.98,"profit":true},{"date":"2024-04-30","value":28.87,"profit":true},{"date":"2025-04-30","value":100,"profit":true}]
Operating Income(57.92M)(96.61M)(110.87M)(140.44M)(188.00M)[{"date":"2021-04-30","value":-5792300000,"profit":false},{"date":"2022-04-30","value":-9661300000,"profit":false},{"date":"2023-04-30","value":-11087100000,"profit":false},{"date":"2024-04-30","value":-14044500000,"profit":false},{"date":"2025-04-30","value":-18799500000,"profit":false}]
Total Non-Operating Income/Expense12.58M15.36M20.20M9.24M8.59M[{"date":"2021-04-30","value":62.3,"profit":true},{"date":"2022-04-30","value":76.07,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":45.78,"profit":true},{"date":"2025-04-30","value":42.55,"profit":true}]
Pre-Tax Income(46.24M)(82.34M)(92.91M)(135.10M)(180.05M)[{"date":"2021-04-30","value":-4624400000,"profit":false},{"date":"2022-04-30","value":-8233900000,"profit":false},{"date":"2023-04-30","value":-9290700000,"profit":false},{"date":"2024-04-30","value":-13509600000,"profit":false},{"date":"2025-04-30","value":-18005200000,"profit":false}]
Income Taxes(1.75M)(13.83M)(18.05M)(8.45M)3.39M[{"date":"2021-04-30","value":-51.59,"profit":false},{"date":"2022-04-30","value":-407.64,"profit":false},{"date":"2023-04-30","value":-532.25,"profit":false},{"date":"2024-04-30","value":-249.17,"profit":false},{"date":"2025-04-30","value":100,"profit":true}]
Income After Taxes(44.49M)(68.51M)(74.85M)(126.64M)(183.44M)[{"date":"2021-04-30","value":-4449400000,"profit":false},{"date":"2022-04-30","value":-6851200000,"profit":false},{"date":"2023-04-30","value":-7485300000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false},{"date":"2025-04-30","value":-18344400000,"profit":false}]
Income From Continuous Operations(46.24M)(82.34M)(92.91M)(126.64M)(183.44M)[{"date":"2021-04-30","value":-4624400000,"profit":false},{"date":"2022-04-30","value":-8233900000,"profit":false},{"date":"2023-04-30","value":-9290700000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false},{"date":"2025-04-30","value":-18344400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true},{"date":"2025-04-30","value":"-","profit":true}]
Net Income(46.24M)(82.34M)(92.91M)(126.64M)(183.44M)[{"date":"2021-04-30","value":-4624400000,"profit":false},{"date":"2022-04-30","value":-8233900000,"profit":false},{"date":"2023-04-30","value":-9290700000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false},{"date":"2025-04-30","value":-18344400000,"profit":false}]
EPS (Diluted)(2.40)(3.36)(3.36)(3.40)(3.69)[{"date":"2021-04-30","value":-240,"profit":false},{"date":"2022-04-30","value":-336,"profit":false},{"date":"2023-04-30","value":-336,"profit":false},{"date":"2024-04-30","value":-340,"profit":false},{"date":"2025-04-30","value":-369,"profit":false}]

Kalvista Pharmaceuticals Inc Ratios

Kalvista Pharmaceuticals Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

KALV
Cash Ratio 6.86
Current Ratio 7.22
Quick Ratio 7.21

Kalvista Pharmaceuticals Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KALV
ROA (LTM) -60.98%
ROE (LTM) -190.18%

Kalvista Pharmaceuticals Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KALV
Debt Ratio Lower is generally better. Negative is bad. 0.95
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.05

Kalvista Pharmaceuticals Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KALV
Trailing PE NM
Forward PE 18.18
P/S (TTM) 531.34
P/B 44.32
Price/FCF NM
EV/R 416.42
EV/Ebitda NM
PEG NM

FAQs

What is Kalvista Pharmaceuticals Inc share price today?

Kalvista Pharmaceuticals Inc (KALV) share price today is $15.45

Can Indians buy Kalvista Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Kalvista Pharmaceuticals Inc (KALV) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KALV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kalvista Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Kalvista Pharmaceuticals Inc (KALV) via the Vested app. You can start investing in Kalvista Pharmaceuticals Inc (KALV) with a minimum investment of $1.

How to invest in Kalvista Pharmaceuticals Inc shares from India?

You can invest in shares of Kalvista Pharmaceuticals Inc (KALV) via Vested in three simple steps:

  • Click on Sign Up or Invest in KALV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kalvista Pharmaceuticals Inc shares
What is Kalvista Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Kalvista Pharmaceuticals Inc (KALV) is $19. The 52-week low price of Kalvista Pharmaceuticals Inc (KALV) is $9.23.

What is Kalvista Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Kalvista Pharmaceuticals Inc (KALV) is

What is Kalvista Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kalvista Pharmaceuticals Inc (KALV) is 44.32

What is Kalvista Pharmaceuticals Inc dividend yield?

The dividend yield of Kalvista Pharmaceuticals Inc (KALV) is 0.00%

What is the Market Cap of Kalvista Pharmaceuticals Inc?

The market capitalization of Kalvista Pharmaceuticals Inc (KALV) is $757.69M

What is Kalvista Pharmaceuticals Inc's stock symbol?

The stock symbol (or ticker) of Kalvista Pharmaceuticals Inc is KALV

How Can Investors Use Kalvista Pharmaceuticals Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Kalvista Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Kalvista Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Kalvista Pharmaceuticals Inc shares for Indian investors?

When investing in Kalvista Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Kalvista Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Kalvista Pharmaceuticals Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Kalvista Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Kalvista Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top